Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 119

1.

Loss of Circulating CD8+ CD161high T Cells in Primary Progressive Multiple Sclerosis.

Acquaviva M, Bassani C, Sarno N, Dalla Costa G, Romeo M, Sangalli F, Colombo B, Moiola L, Martinelli V, Comi G, Farina C.

Front Immunol. 2019 Aug 14;10:1922. doi: 10.3389/fimmu.2019.01922. eCollection 2019.

2.

Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS.

Ghezzi A, Comi G, Grimaldi LM, Moiola L, Pozzilli C, Fantaccini S, Gallo P.

Neurol Neuroimmunol Neuroinflamm. 2019 Jul 1;6(5). pii: e591. doi: 10.1212/NXI.0000000000000591. Print 2019 Sep.

3.

Effects of Natalizumab and Fingolimod on Clinical, Cognitive, and Magnetic Resonance Imaging Measures in Multiple Sclerosis.

Preziosa P, Rocca MA, Riccitelli GC, Moiola L, Storelli L, Rodegher M, Comi G, Signori A, Falini A, Filippi M.

Neurotherapeutics. 2019 Aug 26. doi: 10.1007/s13311-019-00781-w. [Epub ahead of print]

PMID:
31452082
4.

Subclinical neurodegeneration in multiple sclerosis and neuromyelitis optica spectrum disorder revealed by optical coherence tomography.

Pisa M, Ratti F, Vabanesi M, Radaelli M, Guerrieri S, Moiola L, Martinelli V, Comi G, Leocani L.

Mult Scler. 2019 Aug 8:1352458519861603. doi: 10.1177/1352458519861603. [Epub ahead of print]

PMID:
31392924
5.

Performance of SLE responder index and lupus low disease activity state in real life: A prospective cohort study.

Ramirez GA, Canti V, Moiola L, Magnoni M, Rovere-Querini P, Coletto LA, Dagna L, Manfredi AA, Bozzolo EP.

Int J Rheum Dis. 2019 Sep;22(9):1752-1761. doi: 10.1111/1756-185X.13663. Epub 2019 Aug 5.

PMID:
31379114
6.

Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS.

Ghezzi A, Comi G, Grimaldi LM, Moiola L, Pozzilli C, Fantaccini S, Gallo P.

Neurol Neuroimmunol Neuroinflamm. 2019 Jul 1;6(5):e591. doi: 10.1212/NXI.0000000000000591. eCollection 2019 Sep.

7.

In vivo structural and functional assessment of optic nerve damage in neuromyelitis optica spectrum disorders and multiple sclerosis.

Vabanesi M, Pisa M, Guerrieri S, Moiola L, Radaelli M, Medaglini S, Martinelli V, Comi G, Leocani L.

Sci Rep. 2019 Jul 17;9(1):10371. doi: 10.1038/s41598-019-46251-3.

8.

Structural and functional brain connectomes in patients with systemic lupus erythematosus.

Preziosa P, Rocca MA, Ramirez GA, Bozzolo EP, Canti V, Pagani E, Valsasina P, Moiola L, Rovere-Querini P, Manfredi AA, Filippi M.

Eur J Neurol. 2019 Jul 15. doi: 10.1111/ene.14041. [Epub ahead of print]

PMID:
31306535
9.

Caesarean section and infant formula feeding are associated with an earlier age of onset of multiple sclerosis.

Dalla Costa G, Romeo M, Esposito F, Sangalli F, Colombo B, Radaelli M, Moiola L, Comi G, Martinelli V.

Mult Scler Relat Disord. 2019 Aug;33:75-77. doi: 10.1016/j.msard.2019.05.010. Epub 2019 May 21.

PMID:
31158806
10.

Dynamic gray matter volume changes in pediatric multiple sclerosis: A 3.5 year MRI study.

De Meo E, Meani A, Moiola L, Ghezzi A, Veggiotti P, Filippi M, Rocca MA.

Neurology. 2019 Apr 9;92(15):e1709-e1723. doi: 10.1212/WNL.0000000000007267. Epub 2019 Mar 13.

PMID:
30867274
11.

Serum neurofilaments increase at progressive multifocal leukoencephalopathy onset in natalizumab-treated multiple sclerosis patients.

Dalla Costa G, Martinelli V, Moiola L, Sangalli F, Colombo B, Finardi A, Cinque P, Kolb EM, Haghikia A, Gold R, Furlan R, Comi G.

Ann Neurol. 2019 Apr;85(4):606-610. doi: 10.1002/ana.25437. Epub 2019 Mar 5.

PMID:
30761586
12.

Prognostic value of serum neurofilaments in patients with clinically isolated syndromes.

Dalla Costa G, Martinelli V, Sangalli F, Moiola L, Colombo B, Radaelli M, Leocani L, Furlan R, Comi G.

Neurology. 2019 Feb 12;92(7):e733-e741. doi: 10.1212/WNL.0000000000006902. Epub 2019 Jan 11.

13.

Severe disease activity in a patient with multiple sclerosis after daclizumab discontinuation.

Martinelli V, Dalla Costa G, Sangalli F, Colombo B, Robotti M, Moiola L, Comi G.

Mult Scler Relat Disord. 2019 Feb;28:57-59. doi: 10.1016/j.msard.2018.11.034. Epub 2018 Dec 1.

PMID:
30554038
14.

Acquired haemophilia A as a secondary autoimmune disease after alemtuzumab treatment in multiple sclerosis: A case report.

Pisa M, Della Valle P, Coluccia A, Martinelli V, Comi G, D'Angelo A, Moiola L.

Mult Scler Relat Disord. 2019 Jan;27:403-405. doi: 10.1016/j.msard.2018.11.029. Epub 2018 Nov 29.

PMID:
30513503
15.

No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study.

Prosperini L, Annovazzi P, Boffa L, Buscarinu MC, Gallo A, Matta M, Moiola L, Musu L, Perini P, Avolio C, Barcella V, Bianco A, Farina D, Ferraro E, Pontecorvo S, Granella F, Grimaldi LME, Laroni A, Lus G, Patti F, Pucci E, Pasca M, Sarchielli P; Italian Alemtuzumab Study Group.

J Neurol. 2018 Dec;265(12):2851-2860. doi: 10.1007/s00415-018-9070-x. Epub 2018 Sep 26.

PMID:
30259178
16.

Assessing the role of innovative therapeutic paradigm on multiple sclerosis treatment response.

Romeo MAL, Martinelli V, Dalla Costa G, Colombo B, De Feo D, Esposito F, Ferrè L, Guaschino C, Guerrieri S, Liberatore G, Martinelli Boneschi F, Merlini A, Messina M, Messina R, Nuara A, Preziosa P, Radaelli M, Rocca MA, Rodegher M, Sangalli F, Strambo D, Moiola L, Comi G.

Acta Neurol Scand. 2018 Nov;138(5):447-453. doi: 10.1111/ane.12999. Epub 2018 Jul 22.

PMID:
30033621
17.

Basal vitamin D levels and disease activity in multiple sclerosis patients treated with fingolimod.

Ferre' L, Clarelli F, Sferruzza G, Rocca MA, Mascia E, Radaelli M, Sangalli F, Dalla Costa G, Moiola L, Aboulwafa M, Martinelli Boneschi F, Comi G, Filippi M, Martinelli V, Esposito F.

Neurol Sci. 2018 Aug;39(8):1467-1470. doi: 10.1007/s10072-018-3440-0. Epub 2018 May 13.

PMID:
29756179
18.

Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks.

Portaccio E, Annovazzi P, Ghezzi A, Zaffaroni M, Moiola L, Martinelli V, Lanzillo R, Brescia Morra V, Rinaldi F, Gallo P, Tortorella C, Paolicelli D, Pozzilli C, De Giglio L, Cavalla P, Cocco E, Marrosu MG, Patti F, Solaro C, Bellantonio P, Uccelli A, Laroni A, Pastò L, Giannini M, Trojano M, Comi G, Amato MP; MS Study Group of the Italian Neurological Society.

Neurology. 2018 Mar 6;90(10):e823-e831. doi: 10.1212/WNL.0000000000005067. Epub 2018 Feb 7.

PMID:
29438046
19.

Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks.

Portaccio E, Moiola L, Martinelli V, Annovazzi P, Ghezzi A, Zaffaroni M, Lanzillo R, Brescia Morra V, Rinaldi F, Gallo P, Tortorella C, Paolicelli D, Pozzilli C, De Giglio L, Cavalla P, Cocco E, Marrosu MG, Solaro C, Uccelli A, Laroni A, Pastò L, Giannini M, Trojano M, Comi G, Amato MP; MS Study Group of the Italian Neurological Society.

Neurology. 2018 Mar 6;90(10):e832-e839. doi: 10.1212/WNL.0000000000005068. Epub 2018 Feb 7.

PMID:
29438041
20.

Effectiveness and baseline factors associated to fingolimod response in a real-world study on multiple sclerosis patients.

Esposito F, Ferrè L, Clarelli F, Rocca MA, Sferruzza G, Storelli L, Radaelli M, Sangalli F, Moiola L, Colombo B, Martinelli Boneschi F, Comi G, Filippi M, Martinelli V.

J Neurol. 2018 Apr;265(4):896-905. doi: 10.1007/s00415-018-8791-1. Epub 2018 Feb 12.

PMID:
29435643

Supplemental Content

Loading ...
Support Center